Natera, Inc. (NASDAQ:NTRA) CFO Sells $7,694,633.76 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 43,502 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the sale, the chief financial officer now owns 70,629 shares in the company, valued at $12,492,857.52. The trade was a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Stock Down 1.3 %

Natera stock traded down $2.32 during mid-day trading on Friday, hitting $172.82. 857,965 shares of the company's stock were exchanged, compared to its average volume of 1,326,767. Natera, Inc. has a 1-year low of $67.33 and a 1-year high of $183.00. The stock has a 50 day moving average of $167.66 and a two-hundred day moving average of $140.49. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $22.82 billion, a P/E ratio of -98.19 and a beta of 1.66.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.95) earnings per share. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Principal Securities Inc. raised its stake in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after buying an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC raised its position in Natera by 1.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock worth $574,000 after purchasing an additional 61 shares in the last quarter. Silver Oak Securities Incorporated lifted its stake in Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after purchasing an additional 89 shares during the period. Covestor Ltd boosted its holdings in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on NTRA shares. Piper Sandler raised their price objective on Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research report on Monday, November 18th. StockNews.com downgraded Natera from a "hold" rating to a "sell" rating in a report on Thursday, November 14th. JPMorgan Chase & Co. upped their price target on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Finally, Guggenheim upped their target price on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $165.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.